126 related articles for article (PubMed ID: 1445484)
1. Pharmacokinetics and protein binding of gestodene under treatment with a low-dose combination oral contraceptive for three months.
Dibbelt L; Knuppen R; Kuhnz W; Jütting G
Arzneimittelforschung; 1992 Sep; 42(9):1146-52. PubMed ID: 1445484
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and serum protein binding of gestodene and 3-keto-desogestrel in women after single oral administration of two different contraceptive formulations.
Kuhnz W; Schütt B; Power J; Back DJ
Arzneimittelforschung; 1992 Sep; 42(9):1139-41. PubMed ID: 1445482
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and serum protein binding of 3-keto-desogestrel in women during three cycles of treatment with a low-dose combination oral contraceptive.
Kuhnz W; al-Yacoub G; Power J; Ormesher SE; Back DJ; Jütting G
Arzneimittelforschung; 1992 Sep; 42(9):1142-6. PubMed ID: 1445483
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum.
Kuhnz W; Baumann A; Staks T; Dibbelt L; Knuppen R; Jütting G
Contraception; 1993 Oct; 48(4):303-22. PubMed ID: 8222659
[TBL] [Abstract][Full Text] [Related]
5. Group comparison of serum ethinyl estradiol, SHBG and CBG levels in 83 women using two low-dose combination oral contraceptives for three months.
Dibbelt L; Knuppen R; Jütting G; Heimann S; Klipping CO; Parikka-Olexik H
Contraception; 1991 Jan; 43(1):1-21. PubMed ID: 1825969
[TBL] [Abstract][Full Text] [Related]
6. Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6 beta-hydroxycortisol.
Hammerstein J; Daume E; Simon A; Winkler UH; Schindler AE; Back DJ; Ward S; Neiss A
Contraception; 1993 Mar; 47(3):263-81. PubMed ID: 8462317
[TBL] [Abstract][Full Text] [Related]
7. A pharmacokinetic study with a low-dose oral contraceptive containing 20 microg ethinylestradiol plus 100 microg levonorgestrel.
Endrikat J; Blode H; Gerlinger C; Rosenbaum P; Kuhnz W
Eur J Contracept Reprod Health Care; 2002 Jun; 7(2):79-90. PubMed ID: 12201326
[TBL] [Abstract][Full Text] [Related]
8. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
Teichmann A
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of ethinylestradiol and levonorgestrel after administration of two oral contraceptive preparations.
Carol W; Klinger G; Jäger R; Kasch R; Brandstädt A
Exp Clin Endocrinol; 1992; 99(1):12-7. PubMed ID: 1628691
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum.
Kuhnz W; Staks T; Jütting G
Contraception; 1994 Dec; 50(6):563-79. PubMed ID: 7705098
[TBL] [Abstract][Full Text] [Related]
11. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins.
Wiegratz I; Jung-Hoffmann C; Kuhl H
Contraception; 1995 Jun; 51(6):341-6. PubMed ID: 7554973
[TBL] [Abstract][Full Text] [Related]
12. Protein binding of active ingredients and comparison of serum ethinyl estradiol, sex hormone-binding globulin, corticosteroid-binding globulin, and cortisol levels in women using a combination of gestodene/ethinyl estradiol (Femovan) or a combination of desogestrel/ethinyl estradiol (Marvelon) and single-dose ethinyl estradiol bioequivalence from both oral contraceptives.
Hümpel M; Täuber U; Kuhnz W; Pfeffer M; Brill K; Heithecker R; Louton T; Steinberg B; Seifert W; Schütt B
Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):329-33. PubMed ID: 2142574
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation.
Kuhnz W; al-Yacoub G; Fuhrmeister A
Contraception; 1992 Nov; 46(5):455-69. PubMed ID: 1458892
[TBL] [Abstract][Full Text] [Related]
14. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
[TBL] [Abstract][Full Text] [Related]
15. Effects of desogestrel and gestodene in low-dose oral contraceptive combinations on lipid and lipoprotein status. A randomized prospective study.
Granata A; Sobbrio GA; D'Arrigo F; Barillari M; Curasì MP; Egitto M; Trimarchi F; Granese D; Pullè C
Acta Eur Fertil; 1990; 21(3):143-6. PubMed ID: 2149913
[TBL] [Abstract][Full Text] [Related]
16. Serum distribution of two contraceptive progestins: 3-ketodesogestrel and gestodene.
Hammond GL; Bocchinfuso WP; Orava M; Smith CL; van den Ende A; van Enk A
Contraception; 1994 Oct; 50(4):301-18. PubMed ID: 7813219
[TBL] [Abstract][Full Text] [Related]
17. A single-dose and 3-month clinical-pharmacokinetic study with a new combination oral contraceptive.
Heuner A; Kuhnz W; Heger-Mahn D; Richert K; Hümpel M
Adv Contracept; 1995 Sep; 11(3):207-25. PubMed ID: 8533624
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles.
Kuhnz W; Staks T; Jütting G
Contraception; 1993 Dec; 48(6):557-75. PubMed ID: 8131397
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and protein binding of 3-ketodesogestrel and gestodene in the serum of women during 6 cycles of treatment with two low dose oral contraceptives.
Back DJ; Power J; Winkler U; Schindler AE; Daume E; Simon A; Neiss A; Hammerstein J
Adv Contracept; 1993 Dec; 9(4):319-30. PubMed ID: 8147246
[TBL] [Abstract][Full Text] [Related]
20. Alterations in the serum levels of gestodene and SHBG during 12 cycles of treatment with 30 micrograms ethinylestradiol and 75 micrograms gestodene.
Kuhl H; Jung-Hoffmann C; Heidt F
Contraception; 1988 Oct; 38(4):477-86. PubMed ID: 3208516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
